Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Evolent Health, Inc. on June 4, 2026. The filing details the voting outcomes for four proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on four proposals with the following outcomes:
- Proposal 1 (Election of Directors): Ten director nominees were elected. While all were elected, significant "Against" votes were recorded for several nominees, including Toyin Ajayi, MD (5,912,292 against), Seth Blackley (5,993,625 against), Russell Glass (5,982,067 against), Peter Grua (5,961,459 against), Richard Jelinek (6,269,584 against), and Kim Keck (6,131,979 against). Other nominees received significantly fewer "Against" votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was overwhelmingly in favor (82,036,843 For vs. 124,362 Against).
- Proposal 3 (Executive Compensation): Stockholders approved the compensation of named executive officers for 2025 on an advisory basis. The vote was 58,369,473 For and 7,922,802 Against.
- Proposal 4 (Incentive Plan Amendment): Stockholders approved the amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan. The vote was 47,536,873 For and 18,712,636 Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the high "Against" vote percentages for six of the ten director nominees, which ranged from approximately 8.8% to 10.4% of the votes cast.
- Confirm the details of the amendment to the 2015 Omnibus Incentive Compensation Plan approved in Proposal 4, as the filing only states the approval without detailing the specific changes.
- Review the definitive proxy statement filed on April 24, 2026, for the full context of the executive compensation advisory vote (Proposal 3).